Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 171, Issue 5, 2005, Pages 494-499

  Nagaoka, Tetsutaro ^a   Fagan, Karen A ^b   Gebb, Sarah A ^b   Morris, Kenneth G ^b   Suzuki, Tsutomu ^b   Shimokawa, Hiroaki ^b   McMurtry, Ivan F ^b   Oka, Masahiko ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE

Author keywords

Fasudil; Fawn hooded rat; Hypoxia; Monocrotaline; Y 27632

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; FASUDIL; MONOCROTALINE; NITRIC OXIDE; RHO KINASE INHIBITOR;

ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; HYPOXIA; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; TREATMENT OUTCOME; VASODILATATION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; AMIDES; ANIMALS; ANOXIA; BLOOD PRESSURE; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HYPERTENSION, PULMONARY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NITRIC OXIDE; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 15944403568     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200405-637OC     Document Type: Article

References (48)

1. Rounds S, Hill NS. Pulmonary hypertensive diseases. Chest 1984;85:397-405.
2. Reeves JT, Groves BM, Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis 1986;134:342-346.
3. Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 2001;92:1-20.
4. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Crow JW. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334: 296-301.
5. Shapiro SM, Oudiz RJ, Cao T, Romano MA, Beckmann XJ, Georgiou D, Mandayam S, Ginzton LE, Brundage BH. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997;30:343-349.
6. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Rubin LJ. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358:1119-1123.
7. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
8. Janssen LJ, Lu-Chao H, Netherton S. Excitation-contraction coupling in pulmonary vascular smooth muscle involves tyrosine kinase and Rho kinase. Am J Physiol Lung Cell Mol Physiol 2001;280:L666-L674.
9. Damron DS, Kanaya N, Homma Y, Kim SO, Murray PA. Role of PKC, tyrosine kinases, and Rho kinase in ́-adrenoreceptor-mediated PASM contraction. Am J Physiol Lung Cell Mol Physiol 2002;283:L1051-L1064.
10. Robertson TP, Dipp M, Ward JPT, Aaronson PI, Evans AM. Inhibition of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and perfused lung of the rat. Br J Pharmacol 2000; 131:5-9.
11. Wang Z, Jin N, Ganguli S, Swartz DR, Li L, Rhoades RA. Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction. Am J Respir Cell Mol Biol 2001;25:628-635.
12. Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG, McMurtry IF. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 2004;287:L656-L664.
13. Nagaoka T, Morio Y, Casanova N, Bauer NR, Gebb SA, McMurtry IF, Oka M. Rho/Rho-kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 2004;287:L665-L672.
14. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389:990-994.
15. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima K, Kaibuchi K, Takeshita A. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004;94:358-393.
16. Sato K, Webb S, Tucker A, Rabinovitch M, O'Brien RF, McMurtry IF, Stelzner TJ. Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat. Am Rev Respir Dis 1991;145:793-797.
17. Nagaoka T, Muramatsu M, Sato K, McMurtry IF, Oka M, Fukuchi Y. Mild hypoxia causes severe pulmonary hypertension in fawn-hooded but not in Tester Moriyama rats. Respir Physiol 2001;127:53-60.
18. Nagaoka T, Fagan KA, Morris KG, McMurtry IF, Oka M. Inhaled Rho kinase inhibitor is more effective than inhaled nitric oxide as a selective vasodilator in hypoxic pulmonary hypertensive rats [abstract]. Circulation 2003;108:IV-10.
19. Oka M, Hasunuma K, Webb SA, Stelzner TJ, Rodman DM, McMurtry IF. EDRF suppresses an unidentified vasoconstrictor mechanism in hypertensive rat lungs. Am J Physiol Lung Cell Mol Physiol 1993;264: L587-L597.
20. 4- and histamine-induced airflow obstruction and airway microvascular leakage in guinea pigs in vivo. Pharmacology 2002;64:189-195.
21. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 2002;39:319-327.
22. Hu E, Lee D. Rho kinase inhibitors as potential therapeutic agents for cardiovascular diseases. Curr Opin Investig Drugs 2003;4:1065-1075.
23. Gianetti J, Bevilacqua S. De Caterina R. Inhaled nitric oxide: more than a selective pulmonary vasodilator. Eur J Clin Invest 2002;32:628-635.
24. Takahara A, Sugiyama A, Satoh Y, Yoneyama M, Hashimoto K. Cardiovascular effects of Y-27632, a selective Rho-associated kinase inhibitor, assessed in the halothane-anesthetized canine model. Eur J Pharmacol 2003;460:51-57.
25. Chrissobolis S, Sobey CG. Evidence that Rho-kinase activity contributes to cerebral vascular tone in vivo and is enhanced during chronic hypertension. Circ Res 2001;88:774-779.
26. Oka M, Morris KG, McMurtry IF. NIP-121 is more effective than nifedipine in acutely reversing chronic pulmonary hypertension. J Appl Physiol 1993;75:1075-1080.
27. Cohen AH, Hanson K, Morris KG, Fouty B, McMurtry IF, Clarke W, Rodman DM. Inhibition of cyclic 3́-5́-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest 1996;97:172-179.
28. Wensel R, Opitz CF, Ewert R, Bruch L, Kleber FX. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation 2000;101:2388-2392.
29. Opitz CF, Wensel R, Bettmann M, Schaffarczyk R, Linscheid M, Hetzer R, Ewert R. Assessment of the vasodilator response in primary pulmonary hypertension: comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003;24:356-365.
30. Nagaya N, Okumura H, Uematsu M, Shimizu W, Ono F, Shirai M, Mori H, Miyatake K, Kangawa K. Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats. Am J Physiol Heart Circ Physiol 2003;285:H2125-H2131.
31. Nagaya N, Kyotani S, Uematsu M, Ueno K, Oya H, Nakanishi N, Shirai M, Mori K, Miyatake K, Kangawa K. Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation 2004;109:351-356.
32. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, Niedermeyer J, Fabel H, Seeger W. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol 2000;35:176-182.
33. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Seeger W. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-329.
34. 2+ desensitization in pulmonary vascular smooth muscle through inhibition of RhoA/Rho kinase signaling. Am J Physiol Lung Cell Mol Physiol 2004;287:L1220-L1229.
35. Jernigan NL, Resta TC. Chronic hypoxia attenuates cGMP-dependent pulmonary vasodilation. Am J Physiol Lung Cell Mol Physiol 2002; 282:L1366-L1375.
36. Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 2003;107:3230-3235.
37. Iizuka K, Shimizu Y, Tsukagoshi H, Yoshii A, Harada T, Dobashi K, Murozono T, Nakazawa T, Mori M. Evaluation of Y-27632, Rho-kinase inhibitor, as a bronchodilator in guinea pigs. Eur J Pharmacol 2000;406:273-279.
38. Belik J, Pan J, Jankov RP, Tanswell AK. A bronchial epithelium-derived factor reduces pulmonary vascular tone in the newborn rat. J Appl Physiol 2004;96:1399-1405.
39. Fagan KA, McMurtry IF, Rodman DM. Role of endothelin-1 in lung disease. Respir Res 2001;2:90-101.
40. MacLean MR, Herve P, Eddahibi S, Adnot S. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 2000;131:161-168.
41. Wettschureck N, Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med 2002;80:629-638.
42. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003;83:1325-1358.
43. Ghisdal P, Vandenberg G, Morel N. Rho-dependent kinase is involved in agonist-activated calcium entry in rat arteries. J Physiol 2003;551: 855-867.
44. Luykenaar KD, Brett SE, Wu BN, Wiehler WB, Welsh DG. Pyrimidine nucleotides suppress KDR currents and depolarize rat cerebral arteries by activating Rho kinase. Am J Physiol Heart Circ Physiol 2004;286: H1088-H1100.
45. kip1. J Biol Chem 1999;274:21926-21931.
46. Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001;22:32-39.
47. Matsumoto Y, Uwatoku T, Oi K, Hattori T, Morishige K, Eto Y, Fukumoto Y, Nakamura K, Takeshita A, Shimokawa H. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol 2004;24:181-186.
48. Liu Y, Suzuki YJ, Day RM, Fanburg BL. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res 2004;95:579-586.